New Lancet review journal launched

July 31, 2001

Please note that the embargo for this material is 0001 hrs London time Wednesday 1st August, for those outside the US

August 2001 heralds the arrival of THE LANCET INFECTIOUS DISEASES, a new monthly specialty review journal from The Lancet Publishing Group. THE LANCET INFECTIOUS DISEASES (TLID) will provide researchers and clinicians with high-quality information about the latest developments in infectious disease medicine. Every month TLID will deliver thought-provoking editorial comment, and the latest infectious diseases news from around the world. Peer-reviewed articles will give a detailed analysis of specific topics, and the commissioned 'Reflection and Reaction' feature will debate a topical issue of the month. A lively interview with a prominent figure in infectious disease medicine, reviews of relevant literature and websites, and the light-hearted 'Last Word' column will ensure comprehensive and varied coverage.

TLID Editor John McConnell comments: "After a period of neglect, infectious diseases are back at the forefront of medical research. TLID exists to report on our battles with and, hopefully, victories over infectious diseases."


Leading Edge - A gift to be used sparingly

The inaugural editorial discusses the growing problem of inappropriate antibiotic use, a major contributory factor to the emergence of antibiotic-resistant pathogens. It comments how, three years after a meeting of a European Union consortium to tackle the problem, research indicates that antibiotic use is increasing (by over 11% from 1997-99 according to one Swedish estimate). Lack of awareness at a grass-roots level - a recent report revealed how the issue is sparingly discussed in the training of medical students - is highlighted as a major stumbling block. For many general practitioners, uncertainty about diagnosis often leads to the (inappropriate) prescription of broad-spectrum antibiotics. The editorial also challenges the medical community to prioritise the prevention of infectious diseases through control measures such as improved hospital-based hygiene and (where appropriate) effective implementation of vaccination programmes.

Reflection and Reaction - Can we beat MRSA now we know its genome sequence?

Neil Woodford and David Livermore from the UK's Central Public Health Laboratory discuss the implications that the recent sequencing of the meticillin-resistant Staphylococcus aureus (MRSA) genome will have on future infectious disease medicine. They comment that knowing the sequence doesn't mean the MRSA threat is over, but will enable researchers and clinicians to map out a more detailed strategy for tackling MRSA-related disease.


Prospects for better tuberculosis vaccines
An update on the progress to identify a new tuberculosis vaccine; the current BCG vaccine is not effective in some parts of the world, resulting in tuberculosis being one of the top three infectious causes of death worldwide.

Yellow fever: an update

A review of the clinical features of yellow fever, the original viral haemorrhagic fever. Still an untreatable and potentially lethal disease in the absence of protection by vaccination, yellow fever affects as many as 200000 people annually - 1000-fold more people than the deadly Ebola virus.

Can antibiotic-resistant nosocomial infections be controlled?

A review of research into possible solutions to the growing problem of nosocomial (hospital-based) infections, notably meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

Other reviews

Borna disease virus infection in psychiatric patients: are we on the right track? Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes Personal VIEW - Planned interruptions of anti-HIV treatment

Interview - S Ragnar Norrby-Director General of the Swedish Institute for Infectious Disease Control


Related Tuberculosis Articles from Brightsurf:

Scientists find new way to kill tuberculosis
Scientists have discovered a new way of killing the bacteria that cause tuberculosis (TB), using a toxin produced by the germ itself.

Blocking the iron transport could stop tuberculosis
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply.

Tuberculosis: New insights into the pathogen
Researchers at the University of W├╝rzburg and the Spanish Cancer Research Centre have gained new insights into the pathogen that causes tuberculosis.

Unmasking the hidden burden of tuberculosis in Mozambique
The real burden of tuberculosis is probably higher than estimated, according to a study on samples from autopsies performed in a Mozambican hospital.

HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.

Reducing the burden of tuberculosis treatment
A research team led by MIT has developed a device that can lodge in the stomach and deliver antibiotics to treat tuberculosis, which they hope will make it easier to cure more patients and reduce health care costs.

Tuberculosis: Commandeering a bacterial 'suicide' mechanism
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein.

A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.

How damaging immune cells develop during tuberculosis
Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.

How many people die from tuberculosis every year?
The estimates for global tuberculosis deaths by the World Health Organisation (WHO) and the Institute for Health Metrics and Evaluation (IHME) differ considerably for a dozen countries, according to a study led by ISGlobal.

Read More: Tuberculosis News and Tuberculosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to